Abbott cuts 2021 profit forecast on lower COVID-19 testing demand
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Abbott Laboratories (ABT) Falls After Cutting Full-Year Outlook on Lower Demand for Covid-19 Tests
June 1, 2021 10:56 AM EDTShares of Abbott Laboratories (NYSE: ABT) are down 6.5% in todays trading session after the company issued an updated 2021 outlook to reflect lower demand from its diagnostic unit.
The company cited significantly lower recent and projected COVID-19 diagnostic testing demand amid an accelerated vaccination activity.
Hence, the company now expects full-year 2021 EPS of $2.75 to $2.95 and full-year adjusted EPS of $4.30 to $4.50, below the consensus of... More
